JP2018500353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500353A5 JP2018500353A5 JP2017533932A JP2017533932A JP2018500353A5 JP 2018500353 A5 JP2018500353 A5 JP 2018500353A5 JP 2017533932 A JP2017533932 A JP 2017533932A JP 2017533932 A JP2017533932 A JP 2017533932A JP 2018500353 A5 JP2018500353 A5 JP 2018500353A5
- Authority
- JP
- Japan
- Prior art keywords
- solid oral
- pharmaceutically acceptable
- water
- compound
- oral preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096812P | 2014-12-24 | 2014-12-24 | |
| US62/096,812 | 2014-12-24 | ||
| PCT/US2015/000515 WO2016105582A1 (en) | 2014-12-24 | 2015-12-23 | Compositions for ileo-jejunal drug delivery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500353A JP2018500353A (ja) | 2018-01-11 |
| JP2018500353A5 true JP2018500353A5 (cg-RX-API-DMAC10.html) | 2019-02-07 |
| JP6687248B2 JP6687248B2 (ja) | 2020-04-22 |
Family
ID=55361929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533932A Active JP6687248B2 (ja) | 2014-12-24 | 2015-12-23 | 回腸−空腸薬物送達用組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180193274A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3236943B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6687248B2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK3236943T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2942642T3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI3236943T3 (cg-RX-API-DMAC10.html) |
| HR (1) | HRP20230305T1 (cg-RX-API-DMAC10.html) |
| HU (1) | HUE061809T2 (cg-RX-API-DMAC10.html) |
| LT (1) | LT3236943T (cg-RX-API-DMAC10.html) |
| MA (1) | MA41265B1 (cg-RX-API-DMAC10.html) |
| PL (1) | PL3236943T3 (cg-RX-API-DMAC10.html) |
| PT (1) | PT3236943T (cg-RX-API-DMAC10.html) |
| RS (1) | RS64139B1 (cg-RX-API-DMAC10.html) |
| SI (1) | SI3236943T1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2016105582A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900344T1 (it) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| CN106588937B (zh) * | 2017-01-16 | 2018-09-21 | 东莞市真兴贝特医药技术有限公司 | 咪唑并吡嗪类化合物及其制备方法和应用 |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| JP6922085B2 (ja) * | 2017-09-28 | 2021-08-18 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | ４，６，７−三置換 １，２−ジヒドロピロロ［３，４−ｃ］ピリジン／ピリミジン−３−オン誘導体及びその使用 |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| US11576917B2 (en) | 2018-01-20 | 2023-02-14 | Natco Pharma Limited | Pharmaceutical compositions comprising Ibrutinib |
| KR102328682B1 (ko) | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| WO2020057549A1 (en) * | 2018-09-18 | 2020-03-26 | Beijing Innocare Pharma Tech Co., Ltd. | Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide |
| SG11202103861YA (en) * | 2018-11-06 | 2021-05-28 | Beijing Innocare Pharma Tech Co Ltd | Amorphous solid dispersion comprising 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide |
| WO2020102304A1 (en) * | 2018-11-13 | 2020-05-22 | Rain Therapeutics Inc. | Combination of a kinase inhibitor and an electrolyte, compositions and methods comprising the same |
| ES2906316T3 (es) * | 2018-12-10 | 2022-04-18 | Aphaia Ip Ag | Formas farmacéuticas de dosificación oral para el tratamiento de trastornos metabólicos y enfermedades relacionadas mediante la liberación orquestada de enterocinas |
| CN109851725A (zh) * | 2018-12-29 | 2019-06-07 | 华南理工大学 | 纳米纤维素-聚丙烯酰胺-明胶复合水凝胶、其制备方法及应用 |
| EP3981399A4 (en) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF |
| AU2020328598B2 (en) | 2019-08-15 | 2026-07-02 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| AU2020365951B2 (en) | 2019-10-14 | 2026-07-16 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| CA3155373A1 (en) * | 2019-10-24 | 2021-04-29 | Young Il Kim | A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same |
| KR102993352B1 (ko) | 2019-12-20 | 2026-07-22 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태 |
| WO2021150723A1 (en) | 2020-01-22 | 2021-07-29 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| MX2023004998A (es) * | 2020-11-02 | 2023-05-12 | Black Diamond Therapeutics Inc | Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. |
| TN2023000295A1 (en) * | 2021-06-10 | 2025-07-02 | Hikma Pharmaceuticals Usa Inc | Oral dosage forms of ibrutinib |
| CN113855695B (zh) * | 2021-11-01 | 2023-06-06 | 上海理工大学 | 一种结肠释药口服复方药物组合物及其制备方法 |
| CN114181159B (zh) * | 2021-12-28 | 2024-02-20 | 南通大学 | 含2,4,5-三取代嘧啶酰肼衍生物及其制备方法与应用 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| CN116473923B (zh) * | 2023-05-29 | 2024-05-14 | 杭州剂泰医药科技有限责任公司 | 一种奈拉替尼固体分散体组合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140303191A1 (en) * | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| CN104487441B (zh) * | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
| WO2014004707A1 (en) * | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| SMT201900344T1 (it) * | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| EP2941245B1 (en) * | 2013-01-05 | 2024-06-26 | Anji Pharmaceuticals Inc. | Delayed-release composition comprising biguanide |
-
2015
- 2015-12-23 HR HRP20230305TT patent/HRP20230305T1/hr unknown
- 2015-12-23 DK DK15834774.0T patent/DK3236943T3/da active
- 2015-12-23 JP JP2017533932A patent/JP6687248B2/ja active Active
- 2015-12-23 RS RS20230281A patent/RS64139B1/sr unknown
- 2015-12-23 HU HUE15834774A patent/HUE061809T2/hu unknown
- 2015-12-23 ES ES15834774T patent/ES2942642T3/es active Active
- 2015-12-23 FI FIEP15834774.0T patent/FI3236943T3/fi active
- 2015-12-23 MA MA41265A patent/MA41265B1/fr unknown
- 2015-12-23 SI SI201531939T patent/SI3236943T1/sl unknown
- 2015-12-23 PL PL15834774.0T patent/PL3236943T3/pl unknown
- 2015-12-23 US US15/539,100 patent/US20180193274A1/en not_active Abandoned
- 2015-12-23 PT PT158347740T patent/PT3236943T/pt unknown
- 2015-12-23 LT LTEPPCT/US2015/000515T patent/LT3236943T/lt unknown
- 2015-12-23 WO PCT/US2015/000515 patent/WO2016105582A1/en not_active Ceased
- 2015-12-23 EP EP15834774.0A patent/EP3236943B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230305T1 (hr) | Pripravci za ileo-jejunalnu dostavu lijeka | |
| JP6815358B2 (ja) | 時限パルス放出システム | |
| ES2590479T3 (es) | Sistemas de administración de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos | |
| JP4488171B2 (ja) | 有効成分ブデソニドのための医薬組成物 | |
| JP6161701B2 (ja) | 徐放特性及びエタノールの影響に対する耐性を有する医薬又は栄養補助組成物 | |
| ES2582453T3 (es) | Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada | |
| JP2008540419A5 (cg-RX-API-DMAC10.html) | ||
| US20140248341A1 (en) | Alcohol resistant enteric pharmaceutical compositions | |
| EP0524989A1 (en) | CONTROLLED RELEASE MEDICINAL COMPOSITION. | |
| JP2019513800A5 (cg-RX-API-DMAC10.html) | ||
| JP2014208655A5 (cg-RX-API-DMAC10.html) | ||
| HK1214182A1 (zh) | 采用含有中性乙烯基聚合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物 | |
| US20100247645A1 (en) | Pharmaceutical combination of aliskiren and valsartan | |
| JP2012519725A (ja) | 治療薬の徐放性組成物 | |
| CN101010070A (zh) | 药物组合物 | |
| JP2009502908A (ja) | ｐＨ制御パルス送達システム、その調製法及び使用法 | |
| WO2005055955B1 (en) | DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY | |
| WO2007021101A1 (en) | Sustained-release pellet formulation of alpha1-receptor antagonist and process for the preparation thereof | |
| CN1972674B (zh) | 多层形式的药物 | |
| US20150140089A1 (en) | Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity | |
| JP2007530492A (ja) | Ｎ−（２−（２−フタルイミドエトキシ）−アセチル）−ｌ−アラニル−ｄ−グルタミン酸（ｌｋ−４２３）を含む胃耐性の医薬品投薬形態物 | |
| JP2009544684A5 (cg-RX-API-DMAC10.html) | ||
| JP2017506265A5 (cg-RX-API-DMAC10.html) | ||
| EP3166599A1 (en) | Capsule dosage form of metoprolol succinate | |
| TWI434682B (zh) | 用以製備控制釋放口服劑型的配方及方法 |